# Operational Summary 

for the First Half of the Fiscal Year Ending March 31, 2016

November 5, 2015
Mitsubishi Chemical Holdings Corporation

## Table of Contents

Consolidated Financial Statements for 1H of FY2015 ..... Page No.
Statements of Operations ..... 4
Net Sales and Operating Income by Business Segment ..... 5
Net Sales and Operating Income by Business Sub-Segment ..... 6
Analysis of Operating Income ..... 8
Extraordinary Gain and Loss ..... 9
Cash Flows ..... 10
Balance Sheets ..... 11
Statements of Comprehensive Income ..... 12
Consolidated Revised Forecasts for FY2015
Statements of Operations ..... 13
Net Sales and Operating Income by Business Segment ..... 14
Net Sales and Operating Income by Business Sub-Segment ..... 15
Cash Dividends ..... 17
Reference
Capital Expenditure, Depreciation \& Amortization, R\&D Expenses, and Number of Employees by Business Segment ..... 18

## List of Abbreviations

```
FY2015: April 1, 2015-March 31, 2016
    1st Quarter ("1Q") of FY2015: April 1, 2015 - June 30, 2015
    2nd Quarter ("2Q") of FY2015: July 1, 2015 - September 30, 2015
    1st Half ("1H") of FY2015: April 1, 2015 - September 30, 2015
    2nd Half ("2H") of FY2015: October 1, 2015 - March 31, 2016
FY2014: April 1, 2014 - March 31, 2015
    1st Half ("1H") of FY2014: April 1, 2014 - September 30, 2014
MCHC: Mitsubishi Chemical Holdings Corporation
MCC: Mitsubishi Chemical Corporation
MTPC: Mitsubishi Tanabe Pharma Corporation
MPI: Mitsubishi Plastics, Inc.
MRC: Mitsubishi Rayon Co., Ltd
LSII: Life Science Institute, Inc.
TNSC: Taiyo Nippon Sanso Corporation
(Note)
Divisional numbers into following "business sub-segments" under the business segments of Designed Materials, Health Care, Chemicals, or Polymers are approximation for reference purpose only;
Functional Products
Performance Chemicals
Pharmaceuticals
Diagnostics, Clinical Testing and API
Petrochemicals
Carbon
Industrial Gases
Polyolefins and Advanced Polymers
MMA Monomers and Polymers
```


## Consolidated Statements of Operations

| Exchange rate (¥/US\$) | 121.7 | 121.7 | 121.7 | 103.6 | 18.1 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Naphtha price (¥/kl) | 48,800 | 47,200 | 48,000 | 70,400 | $(22,400)$ |


|  | (Billions of Yen) |  |  |  |  | <Reference> |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 1H of FY2015 | 1H of FY2014 | Change | \% | 1H of FY2015 <br> Forecast (announced on Aug. 5) | Change |
| Net sales | 941.0 | 943.6 | 1,884.6 | 1,672.3 | 212.3 | 13\% | 1,930.0 | (45.4) |
| Operating income | 71.0 | 65.4 | 136.4 | 73.7 | 62.7 | 85\% | 110.0 | 26.4 |
| Income (expenses) on financing activities <br> [Dividend income included in above] <br> Equity in Earnings of non-consolidated subsidiaries and affiliates <br> Other non-operating income (expenses) | $(0.6)$ $[3.2]$ 3.5 0.7 | $\begin{gathered} \hline(3.9) \\ {[0.2]} \\ 2.5 \\ (3.4) \\ \hline \end{gathered}$ | $\begin{array}{r} \hline(4.5) \\ {[3.4]} \\ 6.0 \\ (2.7) \\ \hline \end{array}$ | $\begin{array}{r}\text { (1.1) } \\ {[5.4]} \\ 1.7 \\ 2.0 \\ \hline\end{array}$ | $\begin{gathered} \hline(3.4) \\ {[(2.0)]} \\ 4.3 \\ (4.7) \\ \hline \end{gathered}$ |  | $\begin{array}{r} (5.5) \\ {[3.5]} \\ 5.0 \\ (1.0) \\ \hline \end{array}$ | $\begin{gathered} \hline 1.0 \\ {[(0.1)]} \\ 1.0 \\ (1.7) \\ \hline \end{gathered}$ |
| Ordinary income | 74.6 | 60.6 | 135.2 | 76.3 | 58.9 | 77\% | 108.5 | 26.7 |
| Extraordinary gain Extraordinary loss | $\begin{gathered} 3.5 \\ (2.9) \end{gathered}$ | $\begin{gathered} 2.5 \\ (3.8) \end{gathered}$ | $\begin{gathered} 6.0 \\ (6.7) \end{gathered}$ | 16.7 <br> $(9.3)$ <br> 8.7 | (10.7) <br> 2.6 |  | (1.5) | 0.8 |
| Income before income taxes | 75.2 | 59.3 | 134.5 | 83.7 | 50.8 |  | 107.0 | 27.5 |
| Current and deferred income taxes | (24.3) | (21.8) | (46.1) | (30.9) | (15.2) |  | (35.5) | (10.6) |
| Net income (loss) | 50.9 | 37.5 | 88.4 | 52.8 | 35.6 |  | 71.5 | 16.9 |
| Net income (loss) attributable to non-controlling interests | (16.1) | (13.2) | (29.3) | (19.5) | (9.8) |  | (23.5) | (5.8) |
| Net income (loss) attributable to Shareholders of the parent | 34.8 | 24.3 | 59.1 | 33.3 | 25.8 | 78\% | 48.0 | 11.1 |


| Comprehensive income attributable to : | 64.5 | 3.5 | 68.0 | 69.2 | (1.2) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Shareholders of the parent | 44.9 | 0.3 | 45.2 | 47.9 | (2.7) |
| Non-controlling interests | 19.6 | 3.2 | 22.8 | 21.3 | 1.5 |

## Consolidated Net Sales and Operating Income by Business Segment

|  |  |  |  |  |  | (Billions of Yen) | <Reference> |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 1Q | 2Q | $\begin{aligned} & \text { 1H of } \\ & \text { FY2015 } \end{aligned}$ | $\begin{gathered} \text { 1H of } \\ \text { FY2014 } \end{gathered}$ | Change | 1H of FY2015 Forecast (announced on Aug. 5) |
| Total | Net Sales | 941.0 | 943.6 | 1,884.6 | 1,672.3 | 212.3 | 1,930.0 |
|  | Operating Income | 71.0 | 65.4 | 136.4 | 73.7 | 62.7 | 110.0 |
| Electronics Applications | Net Sales | 29.3 | 29.0 | 58.3 | 57.5 | 0.8 | 60.0 |
|  | Operating Income | (0.1) | 0.2 | 0.1 | (1.1) | 1.2 | 0.0 |
| Designed Materials | Net Sales | 201.8 | 210.2 | 412.0 | 399.7 | 12.3 | 425.0 |
|  | Operating Income | 15.8 | 20.3 | 36.1 | 27.1 | 9.0 | 32.0 |
| Health Care | Net Sales | 128.2 | 133.0 | 261.2 | 255.8 | 5.4 | 252.0 |
|  | Operating Income | 25.0 | 22.5 | 47.5 | 39.8 | 7.7 | 31.5 |
| Chemicals | Net Sales | 326.6 | 321.6 | 648.2 | 428.7 | 219.5 | 673.0 |
|  | Operating Income | 21.5 | 9.4 | 30.9 | 1.5 | 29.4 | 32.5 |
| Polymers | Net Sales | 207.7 | 197.1 | 404.8 | 435.1 | (30.3) | 415.0 |
|  | Operating Income | 9.8 | 12.4 | 22.2 | 7.5 | 14.7 | 17.5 |
| Others | Net Sales | 47.4 | 52.7 | 100.1 | $\begin{array}{rr} \hline & 95.5 \\ * 2 & 2.2 \end{array}$ | 4.6 | 105.0 |
|  | Operating Income | 0.5 | 2.3 | 2.8 |  | 0.6 | 0.5 |
| Corporate | Net Sales | - | - | - | - | - | - |
|  | Operating Income | (1.5) | (1.7) | (3.2) | (3.3) | 0.1 | (4.0) |

*1 Including net sales of 282.0 billion yen and operating income of 18.8 billion yen in industrial gases
*2 Effective from FY2015, certain businesses (including businesses in consolidated subsidiaries) have been reclassified from the Chemicals segment and the Others segment to the Designed Materials segment and the Polymers segment. Accordingly, segment information for FY2014 is restated to match.

## Consolidated Net Sales and Operating Income By Business Sub-segment

|  |  |  | 1Q | 2Q |  | $\begin{aligned} & \text { 1H of } \\ & \text { FY2014 } \end{aligned}$ | (Billions of Yen) |  | <Reference> |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $\begin{gathered} \text { 1H of } \\ \text { FY2015 } \end{gathered}$ |  | Change |  | (a) | 1H of FY2015 Forecas (announced on Aug. 5) |
| Electronics Applications |  | Net Sales |  | 29.3 | 29.0 | 58.3 |  | 57.5 | 0.8 | 60.0 |
|  |  | Operating Income | (0.1) | 0.2 | 0.1 | (1.1) |  | 1.2 | 0.0 |
|  | Functional Products | Net Sales | 140.8 | 148.4 | 289.2 | 276.5 | 12.7 | (b) | 297.0 |
|  |  | Operating Income | 8.1 | 12.3 | 20.4 | 14.8 | 5.6 |  | 17.0 |
|  | Performance Chemicals | Net Sales | 61.0 | 61.8 | 122.8 | 123.2 | (0.4) |  | 128.0 |
|  |  | Operating Income | 7.7 | 8.0 | 15.7 | 12.3 | 3.4 | (c) | 15.0 |
|  | Pharmaceuticals | Net Sales | 98.5 | 103.2 | 201.7 | 198.6 | 3.1 | (d) | 191.5 |
|  |  | Operating Income | 23.8 | 21.9 | 45.7 | 37.1 | 8.6 |  | 30.5 |
|  | Diagnostics, Clinical Testing and API | Net Sales | 29.7 | 29.8 | 59.5 | 57.2 | 2.3 |  | 60.5 |
|  |  | Operating Income | 1.2 | 0.6 | 1.8 | 2.7 | (0.9) |  | 1.0 |

*1 All figures are approximation for reference purpose only.
*2 Effective from FY2015, certain businesses (including businesses in consolidated subsidiaries) have been reclassified from the Chemicals segment and the Others segment to the Designed Materials segment and the Polymers segment. Accordingly, segment information for FY2014 is restated to match.

Major reasons for the change:
(a) Profit increased due to rationalization and increased sales for display materials.
(b) Profit increased due to a drop in raw material prices for polyester film, high-performance films, etc.
(c) Profit increased due to a drop in raw material prices and increased sales in lithium-ion battery materials.
(d) Profit increased due to higher royalty revenues and decreased SG\&A expenses.

## Consolidated Net Sales and Operating Income by Business Sub-segment (Continued)

(Billions of Yen)
*1 All figures are approximation for reference purpose only.
*2 Effective from FY2015, certain businesses (including businesses in consolidated subsidiaries) have been reclassified from the Chemicals segment and the Others segment to the Designed Materials segment and the Polymers segment. Accordingly, segment information for FY2014 is restated to match.

| Inventory valuation gain/loss | 1Q | 2Q | $\begin{gathered} \text { 1H of } \\ \text { FY2015 } \end{gathered}$ | $\begin{gathered} \text { 1H of } \\ \text { FY2014 } \end{gathered}$ | Change |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Chemicals (Petrochemicals) | 2.1 | (3.1) | (1.0) | (0.1) | (0.9) |
| Chemicals (Carbon) | (0.2) | (0.4) | (0.6) | (0.7) | 0.1 |
| Polymers | (2.6) | (2.5) | (5.1) | 2.0 | (7.1) |
| Total | (0.7) | (6.0) | (6.7) | 1.2 | (7.9) |

Major reasons for the change:
(a) Profit increased due to firm petrochemical market conditions and the difference in scale of periodic maintenance.
(b) Impacts of the conversion of TNSC to a consolidated subsidiary (FY2014-3Q - )
(c) Profit increased due to a drop in raw material prices for polyolefin business and phenol and polycarbonate chain.
(d) Increased profit due to a drop in raw material prices.

## Analysis of Operating Income


*1 Items included are impacts from inventory valuation gain/loss, etc.
*2 Including impacts of the conversion of TNSC to a consolidated subsidiary (18.8 billion yen)
*3 Effective from FY2015, certain businesses (including businesses in consolidated subsidiaries) have been reclassified from the Chemicals segment and the Others segment to the Designed Materials segment and the Polymers segment. Accordingly, segment information for FY2014 is restated to match.

## Consolidated Extraordinary Gain and Loss

|  | (Billions of Yen) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | $\begin{gathered} \text { 1H of } \\ \text { FY2015 } \end{gathered}$ | $\begin{gathered} \text { 1H of } \\ \text { FY2014 } \end{gathered}$ | Change |
| Net of extraordinary gain and loss | 0.6 | (1.3) | (0.7) | 7.4 | (8.1) |
| Extraordinary gain | 3.5 | 2.5 | 6.0 | 16.7 | (10.7) |
| Gain on sales of investment securities | 1.1 | 2.2 | 3.3 | 2.1 | 1.2 |
| Gain on step acquisitions | 1.9 | - | 1.9 | - | 1.9 |
| Gain on sales of property, plant and equipment | 0.4 | 0.3 | 0.7 | 12.1 | (11.4) |
| Others | 0.1 | - | 0.1 | 2.5 | (2.4) |
| Extraordinary loss | (2.9) | (3.8) | (6.7) | (9.3) | 2.6 |
| Business structure improvement expenses | - | (1.9) | (1.9) | (6.7) | 4.8 |
| Loss on sales of Intercompany securities | (1.7) | - | (1.7) | - | (1.7) |
| Loss on sales and retirement of property, plant and equipment | (0.5) | (0.5) | (1.0) | (1.1) | 0.1 |
| Impairment loss | (0.0) | (0.9) | (0.9) | (1.1) | 0.2 |
| Others | (0.7) | (0.5) | (1.2) | (0.4) | (0.8) |

## Consolidated Cash Flows

|  | Based on statements of cash flows |  |
| :---: | :---: | :---: |
|  | $\begin{aligned} & \text { 1H of } \\ & \text { FY2015 } \end{aligned}$ | $\begin{aligned} & \text { 1H of } \\ & \text { FY2014 } \end{aligned}$ |
| Net cash provided by operating activities | 167.9 | 120.8 |
| Income before income taxes | 134.5 | 83.7 |
| Depreciation and amortization | 87.1 | 64.1 |
| Amortization of goodwill | 9.9 | 7.7 |
| Change in operating receivables/payables | 20.6 | 9.7 |
| Change in Inventories | (8.2) | (2.5) |
| Others | (76.0) | (41.9) |
| Net cash used in investment activities | 5.9 | (72.9) |
| Capital expenditure | (79.0) | (64.7) |
| Sale of assets | 18.3 | 19.8 |
| Investment and loans receivable, etc | 66.6 | (28.0) |
| Free cash flow | 173.8 | 47.9 |
| Net cash used in financing activities | (96.2) | (7.7) |
| Interest bearing debts | (72.5) | 9.3 |
| Dividends, etc. | (23.7) | (17.0) |
| Increase (Decrease) in cash and cash equivalents | 77.6 | 40.2 |
| Effect of exchange rate changes and change in scope of consolidation | 0.5 | 2.9 |
| Cash and cash equivalents at the beginning of the period | 243.1 | 179.6 |
| Cash and cash equivalents at the end of the period | 321.2 | 222.7 |

## Consolidated Balance Sheets

|  | (Billions of Yen) |  |  |
| :---: | :---: | :---: | :---: |
|  | Sep. 30, 2015 | Mar. 31, 2015 | Change |
| Cash and deposits | 244.9 | 236.2 | 8.7 |
| Inventories | 602.8 | 595.5 | 7.3 |
| Trade receivables | 731.6 | 759.9 | (28.3) |
| Others | 241.2 | 265.6 | (24.4) |
| Current assets | 1,820.5 | 1,857.2 | (36.7) |
| Tangible and Intangible fixed assets | 1,664.2 | 1,679.7 | (15.5) |
| Goodwill | 255.8 | 243.8 | 12.0 |
| Investment and Others | 506.3 | 542.3 | (36.0) |
| Non-current assets | 2,426.3 | 2,465.8 | (39.5) |
| Total assets | 4,246.8 | 4,323.0 | (76.2) |


|  | (Billions of Yen) |  |  |
| :---: | :---: | :---: | :---: |
|  | Sep. 30, 2015 | Mar. 31, 2015 | Change |
| Interest-bearing debts | 1,537.9 | 1,603.6 | (65.7) |
| Trade payables | 449.1 | 459.3 | (10.2) |
| Others | 624.2 | 671.5 | (47.3) |
| Liabilities | 2,611.2 | 2,734.4 | (123.2) |
| Shareholders' equity | 924.0 | 874.6 | 49.4 |
| Accumulated other comprehensive income | 91.5 | 106.4 | (14.9) |
| Non-controlling interests, etc. | 620.1 | 607.6 | 12.5 |
| Net assets | 1,635.6 | 1,588.6 | 47.0 |
| Total liabilities and net assets | 4,246.8 | 4,323.0 | (76.2) |


| Net interest-bearing debts (*${ }^{*}$ ) | $1,171.8$ | $1,228.2$ | $(56.4)$ |
| :--- | ---: | ---: | ---: | ---: |
| Net D/E ratio | 1.15 | 1.25 | $(0.10)$ |
| Net D/Eratio (incld. non-controlling interests in the denominator) | 0.72 | 0.77 | $(0.05)$ | | Shareholders' equity | $1,015.6$ | 981.0 | 34.6 |
| :--- | ---: | ---: | ---: |
| Shareholders' equity ratio | $23.9 \%$ | $22.6 \%$ | $1.3 \%$ |

*1. Net interest-bearing debts ( $1,171.8$ billion yen)
$=$ interest bearing debts ( $1,537.9$ billion yen)

- \{cash and cash equivalents ( 321.2 billion yen) + investments of surplus funds (44.9 billion yen)\}


## Consolidated Statements of Comprehensive Income

Exchange rate used to convert balance sheets for foreign subsidiaries

|  | Sep. 2015 | Mar. 2015 |
| :--- | ---: | ---: |
| For subsidiaries with April-March accounting period $(\nexists / U S \$)$ | 120.0 | 120.2 |
| For subsidiaries with April-March accounting period $(\nexists / €)$ | 135.0 | 130.3 |


|  | (Billions of Yen) |  |  |
| :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \text { 1H of } \\ & \text { FY2015 } \end{aligned}$ | $\begin{gathered} \text { 1H of } \\ \text { FY2014 } \end{gathered}$ | Change |
| Net income(loss) attributable to Shareholders of the parent | 59.1 | 33.3 | 25.8 |
| Net income(loss) attributable to non-controlling interests | 29.3 | 19.5 | 9.8 |
| Net income (loss) | 88.4 | 52.8 | 35.6 |
| Other comprehensive income (loss): <br> Net unrealized holding gain (loss) on other securities <br> Gain (loss) on deferred hedges <br> Foreign currency translation adjustments <br> Remeasurements of defined benefit plans <br> Other comprehensive income (loss) for affiliates accounted for using equity method | $\begin{array}{r} (11.3) \\ (0.1) \\ (7.4) \\ (0.4) \\ (1.2) \end{array}$ | $\begin{gathered} 7.2 \\ (0.4) \\ 7.4 \\ (0.4) \\ 2.6 \end{gathered}$ | $\begin{gathered} (18.5) \\ 0.3 \\ (14.8) \\ 0.0 \\ (3.8) \end{gathered}$ |
| Other comprehensive income (loss), net | (20.4) | 16.4 | (36.8) |
| Total comprehensive income (loss) | 68.0 | 69.2 | (1.2) |
| Total comprehensive income (loss) attributable to : Shareholders of the parent Non-controlling interests | $\begin{aligned} & 45.2 \\ & 22.8 \end{aligned}$ | 47.9 21.3 | $(2.7)$ <br> 1.5 |



## Consolidated Net Sales and Operating Income by Business Segment

 (FY2015 Forecast)|  |  |  |  |  |  | Billions of Yen) | <Reference> |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\begin{gathered} 1 \mathrm{H} \\ \text { Actual } \end{gathered}$ | 2 H Forecast | FY2015 Forecast | FY2015 (announc on May 13) | Change | FY2014 Actual |
| Total | Net Sales | 1,884.6 | 2,055.4 | 3,940.0 | 4,000.0 | (60.0) | 3,656.3 |
|  | Operating Income | 136.4 | 111.6 | 248.0 | 227.0 | 21.0 | 165.7 |
| Electronics Applications | Net Sales | 58.3 | 61.7 | 120.0 | 125.0 | (5.0) | 118.8 |
|  | Operating Income | 0.1 | 0.4 | 0.5 | 0.5 | 0.0 | (2.8) |
| Designed Materials | Net Sales | 412.0 | 473.0 | 885.0 | 900.0 | (15.0) | 818.6 |
|  | Operating Income | 36.1 | 31.9 | 68.0 | 66.0 | 2.0 | 55.6 |
| Health Care | Net Sales | 261.2 | 283.8 | 545.0 | 520.0 | 25.0 | 531.9 |
|  | Operating Income | 47.5 | 43.0 | 90.5 | 77.5 | 13.0 | 77.0 |
| Chemicals | Net Sales | 648.2 | 711.8 | 1,360.0 | 1,380.0 | (20.0) | 1,113.9 |
|  | Operating Income | 30.9 | 24.1 | 55.0 | 52.0 | 3.0 | 8.9 |
| Polymers | Net Sales | 404.8 | 405.2 | 810.0 | 850.0 | (40.0) | 873.7 |
|  | Operating Income | 22.2 | 14.8 | 37.0 | 35.0 | 2.0 | 28.0 |
| Others | Net Sales | 100.1 | 119.9 | 220.0 | 225.0 | (5.0) | 199.4 |
|  | Operating Income | 2.8 | 2.2 | 5.0 | 4.0 | 1.0 | 6.1 |
| Corporate | Net Sales | - |  | - | - | - | - |
|  | Operating Income | (3.2) | (4.8) | (8.0) | (8.0) | 0.0 | (7.1) |

[^0]
## Consolidated Net Sales and Operating Income by Business Sub-segment

|  |  |  |  |  |  |  | (Billions of Yen) | <Reference> <br> FY2014 <br> Actual |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | 1H Actual | 2H <br> Forecast | FY2015 Forecast | FY2015 <br> Forecast <br> (announced <br> on May 13) | Change |  |
| Electronics Applications |  | Net Sales | 58.3 | 61.7 | 120.0 | 125.0 | (5.0) | 118.8 |
|  |  | Operating Income | 0.1 | 0.4 | 0.5 | 0.5 | 0.0 | (2.8) |
|  | Functional Products | Net Sales | 289.2 | 335.8 | 625.0 | 640.0 | (15.0) | 570.4 |
|  |  | Operating Income | 20.4 | 18.1 | 38.5 | 38.5 | 0.0 | 31.3 |
|  | Performance Chemicals | Net Sales | 122.8 | 137.2 | 260.0 | 260.0 | 0.0 | 248.2 |
|  |  | Operating Income | 15.7 | 13.8 | 29.5 | 27.5 | 2.0 | 24.3 |
|  | Pharmaceuticals | Net Sales | 201.7 | 216.3 | 418.0 | 396.0 | 22.0 | 414.8 |
|  |  | Operating Income | 45.7 | 40.8 | 86.5 | 72.0 | 14.5 | 71.5 |
|  | Diagnostics, Clinical Testing and API | Net Sales | 59.5 | 67.5 | 127.0 | 124.0 | 3.0 | 117.1 |
|  |  | Operating Income | 1.8 | 2.2 | 4.0 | 5.5 | (1.5) | 5.5 |

*1 Effective from FY2015, certain businesses (including businesses in consolidated subsidiaries) have been reclassified from the Chemicals segment and the Others segment to the Designed Materials segment and the Polymers segment. Accordingly, segment information for FY2014 is restated to match.

Major reasons for the change:
(a) Profit increased due to higher royalty revenues.

## Consolidated Net Sales and Operating Income by Business Sub-segment (Continued)


*1 Effective from FY2015, certain businesses (including businesses in consolidated subsidiaries) have been reclassified from the Chemicals segment and the Others segment to the Designed Materials segment and the Polymers segment. Accordingly, segment information for FY2014 is restated to match.

Major reasons for the change:
(a) Profit increased due to firm petrochemical market conditions in the first half of FY2015, despite decreased profit in PTA business.
(b) Profit increased due to strong performance in Thermos business and impacts of the conversion of TNSC to a consolidated subsidiary.
(c) Profit increased due to increased margins in polyolefin business in the first half of FY2015.

## Cash Dividends

|  |  | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cash dividends per share (Yen) | Interim | 7 | 6 | 6 | 6 | 5 |
|  | Year-end | ${ }^{1} 17$ | 7 | 6 | 6 | 5 |
|  | Total (Annual) | *1 14 | 13 | 12 | 12 | 10 |

*1 Forecast

## Consolidated Capital Expenditure, Depreciation \& Amortization,

 R\&D Expenses, and Number of Employees by Business Segment|  | Capital Expenditure |  |  <br> Amortization <br> (excluding goodwill) |  | R\&D Expenses |  | Number of Employees |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \text { 1H of } \\ & \text { FY2015 } \end{aligned}$ | $\begin{gathered} \text { 1H of } \\ \text { FY2014 } \end{gathered}$ | $\begin{aligned} & \text { 1H of } \\ & \text { FY2015 } \end{aligned}$ | $\begin{aligned} & \text { 1H of } \\ & \text { FY2014 } \end{aligned}$ | $\begin{gathered} \text { 1H of } \\ \text { FY2015 } \end{gathered}$ | $\begin{gathered} \text { 1H of } \\ \text { FY2014 } \end{gathered}$ | 1H of FY2015 <br> (End of the period) |
| Electronics Applications | 1.9 | 3.1 | 3.0 | 2.9 | 3.7 | 4.4 | 2,659 |
| Designed Materials | 20.4 | 23.9 | 20.2 | 19.4 | 10.4 | 10.3 | 16,925 |
| Health Care | 7.9 | 9.7 | 7.9 | 7.7 | 38.5 | 36.9 | 12,673 |
| Chemicals | 29.2 | 12.3 | 33.5 | 13.4 | 2.1 | 1.0 | 18,523 |
| Polymers | 10.8 | 14.1 | 20.2 | 18.3 | 7.4 | 6.6 | 8,026 |
| Others | 1.4 | 1.5 | 1.5 | 1.5 | 0.1 | 0.2 | 9,372 |
| Corporate | 0.8 | 0.9 | 0.8 | 0.9 | 2.3 | 2.3 | 791 |
| Total | 72.4 | 65.5 | 87.1 | 64.1 | 64.5 | 61.7 | 68,969 |

[^1]The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control.

Actual results could differ materially due to numerous factors, including without limitation, marketing conditions and the effects of industry competition.


[^0]:    *1 Effective from FY2015, certain businesses (including businesses in consolidated subsidiaries) have been reclassified from the Chemicals segment and the Others segment to the Designed Materials segment and the Polymers segment. Accordingly, segment information for FY2014 is restated to match.

[^1]:    *1 Effective from FY2015, certain businesses (including businesses in consolidated subsidiaries) have been reclassified from the Chemicals segment and the Others segment to the Designed Materials segment and the Polymers segment. Accordingly, segment information for FY2014 is restated to match.

